fibrillation is associated with significant morbidity and mortality. There is a
strong relationship between atrial fibrillation and aging, thromboembolism,
stroke, congestive heart failure and hypertension. On the other hand, advanced
age confers a powerful risk factor for stroke and thromboembolism in patients
with atrial fibrillation.
For many years,
vitamin K antagonists were the only approved anticoagulants for the management
of atrial fibrillation. Lately new anticoagulants made their appearance and
large trials have already shown their superiority against vitamin K
antagonists. Since the arrhythmia is encountered frequently in the elderly, it
is crucial to identify the beneficial effects of the novel oral anticoagulants
in this particular patient population.
Credits: Konstantina Mitrousi; Gregory Y H Lip; Stavros Apostolakis